US approves breakthrough drug for severe fatty liver disease
The US Food and Drug Administration (FDA) approved the first-ever medication targeting a severe variant of non-alcoholic fatty liver disease (NAFLD) on Thursday. Madrigal Pharmaceuticals’ Rezdiffra had clinched regulatory approval following compelling evidence of its efficacy in combating liver scarring among patients suffering from non-alcoholic steatohepatitis (NASH), the most severe form of NAFLD. NASH has […]